IPSC compared with LENZ: revenue, margins and what each company keeps, and the suppliers and customers both name

IPSCCentury Therapeutics, Inc.

Mkt capRevenueRevenue

LENZLENZ Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

IPSCCentury Therapeutics, Inc.

LENZLENZ Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

IPSC1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±29.8%▼−4.85%×0.16

LENZ

1 of 3at or beyond implied

Reportimpliedrealized× implied

Q3 FY26—▲+8.72%—

Q2 FY26±11.3%▼−3.26%×0.29

= impliedIPSC realized, solidLENZ realized, hatchedOne scale, both sides: full bar = 30%× = |realized| ÷ impliedSource: market data

May 12 '26

±13.5%

▼−20.82%

×1.54

Q1 FY26±20.6%▼−17.91%×0.87

IPSCCentury Therapeutics, Inc.

1.70▲+12.33%· post 1.70

Mkt cap$304.2MRevenue$109MQ1 FY25Revenue$7MFY24

LENZLENZ Therapeutics, Inc.

3.49▲+15.96%· post 3.49

ClosedNov 6 '26

Mkt cap$110.0MRevenue$3MQ3 FY26Revenue—

Compare

ClosedNov 6 '26

IPSCCentury Therapeutics, Inc.

LENZLENZ Therapeutics, Inc.

1.70▲+12.33%post 1.70

Price

3.49▲+15.96%post 3.49

$304.2M

Mkt cap

$110.0M

Q1 FY25$109M

Revenue

$3MQ3 FY26

FY24$7M

Revenue

—

IPSC1.70▲+12.33%vsLENZ3.49▲+15.96%ClosedNov 6 '26